Introduction
The introduction of highly active antiretroviral therapy (HAART) has led to a significant reduction in acquired immune deficiency syndrome (AIDS)-related morbidity and mortality. Unfortunately, up to 25% of all patients discontinue their initial HAART regimen because of treatment failure, toxic effects or noncompliance within the first eight months of therapy. [1],[2] Several strategies have been implemented to improve treatment duration. Due to the ongoing development of new antiretroviral agents, prompt understanding and management of adverse effects becomes very important.
The sustained benefits of HAART have led to far greater numbers of HIV-1 infected cases receiving at ...